

Patient Name: **EXAMPLE, PATIENT**
 Med. Rec. #:
 DOB: 8/12/1966 (Age: 47)
 Gender: F
 Physician(s): UNIDENTIFIED PHYSICIAN

Client:
 Location:
 Billing #:
 Copy To:

Accession #: **ABC-123**
 Taken: 1/31/2014
 Received: 2/1/2014
 Reported: 2/5/2014

Specimen(s) Received

A: Right Renal Aspirate

Clinical History

Ureteral Stricture


Other Case Numbers

1234567

Cytogenetic Analysis

Interpretation

The results are negative. No gains of chromosomes 3, 7, 17 and loss of chromosome 9p21 locus were observed.



UROVYSION FISH

Result

nuc ish(D3Z1,D7Z1,p16,D17Z1)x2[200]

Molecular Cytogenetic Analysis:

FISH
 No. of Cells Analyzed: 200
 No. of Cells Imaged: 3

Method: UroVysion™ (Abbott Molecular Inc., Des Plaines, IL 60018) bladder cancer kit is an FDA approved test designed to detect aneuploidy of chromosome 3, 7, 17 and loss of chromosome 9p21 locus via Fluorescence in situ hybridization (FISH) in urine specimens from patients with hematuria suspected of having bladder cancer. The test uses centromere probes for chromosome 3 (D3Z1), 7 (D7Z1), 17 (D17Z1) and a locus specific probe for 9p21.

DNA Probe	*Patient Cells	
	Total # Cells Studied	Abnormal # %
CEP3/CEP7/p16(9p21)/CEP17	200	0 0

*Concurrent controls are run.

Laboratory test results should always be considered in the context of clinical observations. This FISH test is performed using a Vysis FDA modified UroVysion Kit.

Technical and Professional services performed at: med fusion, 2501 South State Hwy 121, Suite 1100, Lewisville, TX 75067

Electronically Signed Out Saurabh Gupta, Ph.D.,
DABMG

SAMPLE REPORT